Monocyte chemoattractant protein-1 in patients with different types of diabetes mellitus: clinical and practical significance
Background. Monocyte chemoattractant protein-1 (MCP-1) plays a crucial role in inflammatory processes by recruiting monocytes and macrophages to sites of inflammation. Inflammation is closely linked to poor control of diabetes mellitus (DM), characterized by significant glycemic fluctuations and pro...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ZAO "Consilium Medicum"
2025-01-01
|
| Series: | Consilium Medicum |
| Subjects: | |
| Online Access: | https://consilium.orscience.ru/2075-1753/article/viewFile/641776/203565 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849706509255049216 |
|---|---|
| author | Ivan I. Golodnikov Margarita D. Samsonova Irina V. Kononenko Tatiana V. Nikonova Elizaveta S. Podshivalova Ekaterina K. Markelova Ekaterina V. Bondarenko Marina Yu. Loginova Marina V. Shestakova |
| author_facet | Ivan I. Golodnikov Margarita D. Samsonova Irina V. Kononenko Tatiana V. Nikonova Elizaveta S. Podshivalova Ekaterina K. Markelova Ekaterina V. Bondarenko Marina Yu. Loginova Marina V. Shestakova |
| author_sort | Ivan I. Golodnikov |
| collection | DOAJ |
| description | Background. Monocyte chemoattractant protein-1 (MCP-1) plays a crucial role in inflammatory processes by recruiting monocytes and macrophages to sites of inflammation. Inflammation is closely linked to poor control of diabetes mellitus (DM), characterized by significant glycemic fluctuations and prolonged hyperglycemia, as well as subclinical, low-grade inflammation of adipose tissue in type 2 DM. Elevated levels of MCP-1 have been associated with both type 1 and type 2 DM; however, data on its role in the pathogenesis of latent autoimmune diabetes in adults (LADA) are extremely limited.
Aim. To evaluate MCP-1 levels and their association with glycemic control parameters in patients with different types of DM (type 1 DM, type 2 DM, and LADA).
Materials and methods. Between February and November 2023, 80 individuals participated in the study, divided into four groups: patients with type 1 DM (n = 22), type 2 DM (n = 22), LADA (n = 14), and healthy volunteers (n = 22). The median ages were 26 years [21; 32] for type 1 DM, 41 years [33; 51] for type 2 DM, 41 years [33; 46] for LADA, and 33 years [26; 40] for healthy controls. Inclusion criteria were age between 18 and 55 years, body mass index up to 35 kg/m², and a diagnosis of one of the specified forms of DM. Exclusion criteria included other systemic autoimmune diseases, pancreatic diseases, and the use of immunosuppressive therapy.
Results. MCP-1 levels were significantly higher in patients with type 1 DM (213 [162; 263] pg/ml) and type 2 DM (228 [168; 294] pg/ml) compared to healthy volunteers (174 [151; 207] pg/ml; p 0.05). Patients with LADA showed a non-significant trend toward elevated MCP-1 levels (218.51 [160; 268] pg/ml; p 0.05). ROC analysis indicated that MCP-1 is not suitable as an additional marker for the differential diagnosis of LADA.
Conclusion. Elevated MCP-1 levels in patients with type 1 and type 2 DM suggest its possible involvement in the pathogenesis of these diabetes types. The lack of significant MCP-1 elevation in patients with LADA limits its utility as a diagnostic marker for this condition. |
| format | Article |
| id | doaj-art-25e21112abdd40a79e2aed812c71e9b2 |
| institution | DOAJ |
| issn | 2075-1753 2542-2170 |
| language | Russian |
| publishDate | 2025-01-01 |
| publisher | ZAO "Consilium Medicum" |
| record_format | Article |
| series | Consilium Medicum |
| spelling | doaj-art-25e21112abdd40a79e2aed812c71e9b22025-08-20T03:16:11ZrusZAO "Consilium Medicum"Consilium Medicum2075-17532542-21702025-01-0127423924410.26442/20751753.2025.4.2030954919Monocyte chemoattractant protein-1 in patients with different types of diabetes mellitus: clinical and practical significanceIvan I. Golodnikov0https://orcid.org/0000-0003-0935-9004Margarita D. Samsonova1https://orcid.org/0000-0003-2852-807XIrina V. Kononenko2https://orcid.org/0000-0003-4929-1526Tatiana V. Nikonova3https://orcid.org/0000-0001-5656-2596Elizaveta S. Podshivalova4https://orcid.org/0009-0002-4275-847XEkaterina K. Markelova5https://orcid.org/0009-0000-9301-8848Ekaterina V. Bondarenko6https://orcid.org/0000-0003-2122-2297Marina Yu. Loginova7https://orcid.org/0000-0003-3775-4466Marina V. Shestakova8https://orcid.org/0000-0002-5057-127XEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreBackground. Monocyte chemoattractant protein-1 (MCP-1) plays a crucial role in inflammatory processes by recruiting monocytes and macrophages to sites of inflammation. Inflammation is closely linked to poor control of diabetes mellitus (DM), characterized by significant glycemic fluctuations and prolonged hyperglycemia, as well as subclinical, low-grade inflammation of adipose tissue in type 2 DM. Elevated levels of MCP-1 have been associated with both type 1 and type 2 DM; however, data on its role in the pathogenesis of latent autoimmune diabetes in adults (LADA) are extremely limited. Aim. To evaluate MCP-1 levels and their association with glycemic control parameters in patients with different types of DM (type 1 DM, type 2 DM, and LADA). Materials and methods. Between February and November 2023, 80 individuals participated in the study, divided into four groups: patients with type 1 DM (n = 22), type 2 DM (n = 22), LADA (n = 14), and healthy volunteers (n = 22). The median ages were 26 years [21; 32] for type 1 DM, 41 years [33; 51] for type 2 DM, 41 years [33; 46] for LADA, and 33 years [26; 40] for healthy controls. Inclusion criteria were age between 18 and 55 years, body mass index up to 35 kg/m², and a diagnosis of one of the specified forms of DM. Exclusion criteria included other systemic autoimmune diseases, pancreatic diseases, and the use of immunosuppressive therapy. Results. MCP-1 levels were significantly higher in patients with type 1 DM (213 [162; 263] pg/ml) and type 2 DM (228 [168; 294] pg/ml) compared to healthy volunteers (174 [151; 207] pg/ml; p 0.05). Patients with LADA showed a non-significant trend toward elevated MCP-1 levels (218.51 [160; 268] pg/ml; p 0.05). ROC analysis indicated that MCP-1 is not suitable as an additional marker for the differential diagnosis of LADA. Conclusion. Elevated MCP-1 levels in patients with type 1 and type 2 DM suggest its possible involvement in the pathogenesis of these diabetes types. The lack of significant MCP-1 elevation in patients with LADA limits its utility as a diagnostic marker for this condition.https://consilium.orscience.ru/2075-1753/article/viewFile/641776/203565type 1 diabetes mellitustype 2 diabetes mellituslatent autoimmune diabetes in adultsmcp-1inflammatory markers |
| spellingShingle | Ivan I. Golodnikov Margarita D. Samsonova Irina V. Kononenko Tatiana V. Nikonova Elizaveta S. Podshivalova Ekaterina K. Markelova Ekaterina V. Bondarenko Marina Yu. Loginova Marina V. Shestakova Monocyte chemoattractant protein-1 in patients with different types of diabetes mellitus: clinical and practical significance Consilium Medicum type 1 diabetes mellitus type 2 diabetes mellitus latent autoimmune diabetes in adults mcp-1 inflammatory markers |
| title | Monocyte chemoattractant protein-1 in patients with different types of diabetes mellitus: clinical and practical significance |
| title_full | Monocyte chemoattractant protein-1 in patients with different types of diabetes mellitus: clinical and practical significance |
| title_fullStr | Monocyte chemoattractant protein-1 in patients with different types of diabetes mellitus: clinical and practical significance |
| title_full_unstemmed | Monocyte chemoattractant protein-1 in patients with different types of diabetes mellitus: clinical and practical significance |
| title_short | Monocyte chemoattractant protein-1 in patients with different types of diabetes mellitus: clinical and practical significance |
| title_sort | monocyte chemoattractant protein 1 in patients with different types of diabetes mellitus clinical and practical significance |
| topic | type 1 diabetes mellitus type 2 diabetes mellitus latent autoimmune diabetes in adults mcp-1 inflammatory markers |
| url | https://consilium.orscience.ru/2075-1753/article/viewFile/641776/203565 |
| work_keys_str_mv | AT ivanigolodnikov monocytechemoattractantprotein1inpatientswithdifferenttypesofdiabetesmellitusclinicalandpracticalsignificance AT margaritadsamsonova monocytechemoattractantprotein1inpatientswithdifferenttypesofdiabetesmellitusclinicalandpracticalsignificance AT irinavkononenko monocytechemoattractantprotein1inpatientswithdifferenttypesofdiabetesmellitusclinicalandpracticalsignificance AT tatianavnikonova monocytechemoattractantprotein1inpatientswithdifferenttypesofdiabetesmellitusclinicalandpracticalsignificance AT elizavetaspodshivalova monocytechemoattractantprotein1inpatientswithdifferenttypesofdiabetesmellitusclinicalandpracticalsignificance AT ekaterinakmarkelova monocytechemoattractantprotein1inpatientswithdifferenttypesofdiabetesmellitusclinicalandpracticalsignificance AT ekaterinavbondarenko monocytechemoattractantprotein1inpatientswithdifferenttypesofdiabetesmellitusclinicalandpracticalsignificance AT marinayuloginova monocytechemoattractantprotein1inpatientswithdifferenttypesofdiabetesmellitusclinicalandpracticalsignificance AT marinavshestakova monocytechemoattractantprotein1inpatientswithdifferenttypesofdiabetesmellitusclinicalandpracticalsignificance |